MISSOULA – We answer your medical questions every Wednesday on Montana This Morning during Morning Rounds.
If you have a question that you’d like us to answer, just send us an email at firstname.lastname@example.org.
Dr. Blair Davison with St. Patrick Hospital talks about eczema during the May 29, 2019 edition of Morning Rounds.
The National Institue of Allergy and Infectious Diseases has more information about eczema on their website, including the following:
Atopic dermatitis, also known as eczema, is a non-contagious inflammatory skin condition. It is a chronic disease characterized by dry, itchy skin that can weep clear fluid when scratched. People with eczema also may be particularly susceptible to bacterial, viral, and fungal skin infections.
Why Is the Study of Eczema (Atopic Dermatitis) a Priority for NIAID?
Eczema, or atopic dermatitis, is an inflammatory skin condition that affects an estimated 30 percent of the U.S. population, mostly children and adolescents. It is a chronic disease characterized by dry, itchy skin that can weep clear fluid when scratched. People with eczema also may be particularly susceptible to bacterial, viral, and fungal skin infections.
How Is NIAID Addressing This Critical Topic?
NIAID conducts and supports basic research in allergy and immunology that increases our understanding of the immune system and how it contributes to the development of atopic dermatitis and its complications. NIAID also funds patient-centered research to explore the genetic determinants of eczema and to evaluate new strategies to prevent and treat the disease.